LightIntegra Technology, a Vancouver, BC-based developer of a 5-minute test for platelet activation status, received $5.3m in Series A funding.
The round was led by Genome BC and Boardwalk Ventures Inc. and includes funding from Tower Beach Capital Ltd., Coleco Investments, and Quimby Investments (VCC) Ltd.
The company intends to use the funds to bring its test to the US market.
Led by William Dubiel, President and CEO, LightIntegra Technology has advanced ThromboLUX, a non-invasive, rapid optical test that assesses platelet activation status, which does not require dilution. As a routine test for platelet concentrates, it identifies which platelet units may be best suited for prophylaxis and which units may be best suited for therapeutic use.
The medical diagnostics company launched from the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer.